Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter

Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter

US-based Stereotaxis, Inc. (NYSEAMERICAN: STXS) and its Chinese partner Shanghai MicroPort EP Medtech Co., Ltd. (SHA: 688351, MicroPort EP) have jointly announced the receipt of marketing approval from the National Medical Products Administration (NMPA) of China for their co-developed Magbot magnetic navigation ablation catheter. This approval marks a significant milestone in the collaboration between the two companies, bringing an innovative treatment option to the Chinese market.

Magbot Catheter’s Unique Features and System Integration
The Magbot catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed to work exclusively with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN, and MicroPort EP’s Columbus 3D EP Mapping System. This integration ensures precise navigation and control during ablation procedures, enhancing the safety and efficacy of the treatment.

Approved Indications for the Magbot Catheter
The Magbot catheter is approved for the ablation of drug-resistant persistent atrial fibrillation, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia. These approvals underscore the catheter’s potential to improve patient outcomes in the treatment of complex cardiac arrhythmias.

Implications for Cardiac Ablation Procedures in China
The marketing approval of the Magbot catheter by the NMPA highlights the growing presence of advanced cardiac ablation technologies in China. This development not only expands the treatment options available to Chinese patients but also strengthens the partnership between Stereotaxis and MicroPort EP, signaling a commitment to innovation in cardiac care.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry